Alnylam Pharmaceuticals Inc (ALNY)vsCG Oncology, Inc. Common stock (CGON)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CGON
CG Oncology, Inc. Common stock
$65.81
+3.09%
HEALTHCARE · Cap: $5.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 91829% more annual revenue ($3.71B vs $4.04M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
CGON
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for CGON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
4.1% revenue growth
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CGON
The strongest argument for CGON centers on Altman Z-Score.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CGON
The primary concerns for CGON are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CGON is a value play — different risk/reward profiles.
CGON carries more volatility with a beta of 1.19 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 32/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company focused on innovating cancer therapies, with its lead asset, CG0070, being an oncolytic virus therapy designed specifically for non-muscle invasive bladder cancer. The company's strategic commitment to addressing significant unmet needs in oncology emphasizes its potential impact on patient outcomes and treatment paradigms. As CG Oncology progresses through clinical trials and approaches key regulatory milestones, it leverages its proprietary platform to position itself favorably in the competitive oncology landscape. This strategic focus on pioneering therapeutic solutions presents a compelling opportunity for institutional investors seeking to invest in transformative advancements in cancer care.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?